Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
16 November 2023 - 1:00AM
Business Wire
--Povetacicept Superior to Wild-Type TACI-Fc
and B-cell Depletion in a Preclinical Model of Lupus--
-- Initiation of Phase 2 SLE Study Planned for
2H 2024 --
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
announced today that the Company presented new translational data
for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE)
at the American College of Rheumatology Convergence 2023, November
10-15, 2023.
Povetacicept Presentation Highlights Include:
- In SLE patients, BAFF- and APRIL-related genes (i.e., BAFF,
APRIL, TACI, and BCMA) are increased in myeloid lineage cells and B
cells compared to healthy adults.
- Povetacicept, as compared to single BAFF or APRIL pathway
inhibitors, more potently downregulates genes associated with
activation in B cells.
- Povetacicept significantly reduces multiple disease parameters
in a mouse model of lupus, more effectively than WT TACI-Fc or
conventional B cell depletion.
“SLE is a serious, potentially fatal disease with few approved
and effective treatment options,” said Stanford Peng, M.D., Ph.D.,
President and Head of Research and Development at Alpine. “BAFF and
APRIL have been heavily implicated in its pathogenesis, and these
data indicate that potent inhibition of both may be required to
achieve optimal efficacy. Along with the encouraging clinical data
we presented earlier this week with povetacicept in
glomerulonephritis, particularly IgA nephropathy, we look forward
to advancing povetacicept into a phase 2 clinical study in SLE next
year.”
American College of Rheumatology
Convergence 2023 Date/Time: Tuesday, November 14,
2023, 9:00 am – 11:00 am PT Poster Title: Upregulation of
Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests
Non-Redundant Roles, Further Revealed by Dual Inhibition with
Povetacicept (ALPN-303) Abstract ID: 1553950 Session
Name: SLE – Treatment Poster III Location: Exhibit Hall,
San Diego Convention Center, San Diego, CA Presenter:
Tiffany Blair, Ph.D., Alpine Immune Sciences Link to Poster:
https://bit.ly/3ssynXM
About Povetacicept
(ALPN-303)
Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell
activating factor) and APRIL (a proliferation inducing ligand)
cytokines, which play key roles in pathogenesis of multiple
autoimmune diseases via their roles in the activation,
differentiation and/or survival of B cells, particularly
antibody-secreting cells, as well as T cells and innate immune
cells. Based upon an engineered TACI (transmembrane activator and
CAML interactor) domain, povetacicept has exhibited greater potency
in preclinical studies versus wild-type TACI-based comparators, as
well as other inhibitors of BAFF and/or APRIL alone and B cell
depletion. Povetacicept is in development for multiple autoimmune
diseases, including systemic lupus erythematosus, IgA nephropathy
and other autoimmune kidney diseases, and autoimmune
cytopenias.
About Alpine Immune
Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X
and LinkedIn.
Forward-Looking
Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies; the timing of and
results from clinical trials and preclinical development
activities; clinical and regulatory objectives and the timing
thereof; expectations regarding the sufficiency of cash, cash
equivalents, restricted cash, and investments to fund our planned
operations through 2025; the potential efficacy, safety profile,
future development plans, addressable market, regulatory success,
and commercial potential of our product candidates; our ability to
achieve additional milestones in our collaborations and proprietary
programs; the progress and potential of our ongoing development
programs; the timing of our public presentations and potential
publication of future clinical data; the efficacy of our clinical
trial designs; anticipated enrollment in our clinical trials and
the timing thereof; expectations regarding our ongoing
collaborations; and our ability to successfully develop and achieve
milestones in our development programs. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“intend,” and other similar expressions, among others. These
forward-looking statements are based on current assumptions that
involve risks, uncertainties, and other factors that may cause
actual results, events, or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our product candidates;
our ongoing discovery and preclinical efforts may not yield
additional product candidates; our discovery-stage and preclinical
programs may not advance into the clinic or result in approved
products; any of our product candidates may fail in development,
may not receive required regulatory approvals, or may be delayed to
a point where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs; the
impact of competition; adverse conditions in the general domestic
and global economic markets; the impact of pandemics, or other
related health crises on our business, research and clinical
development plans and timelines and results of operations,
including the impact on our clinical trial sites, collaborators,
and contractors who act for or on our behalf; as well as the other
risks identified in our filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof and we undertake no obligation to update
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231115599226/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Apr 2024 to May 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From May 2023 to May 2024